tldrdaily.news logo

FDA Approves Moderna's RSV Vaccine for Seniors

1 min read
Source: Reuters
FDA Approves Moderna's RSV Vaccine for Seniors
Photo: Reuters
TL;DR Summary

The US FDA has approved Moderna's RSV vaccine, mRESVIA, for adults aged 60 and older, with a label indicating 79% efficacy, lower than the 84% initially reported. This approval marks the first non-COVID-19 mRNA vaccine in the US. Moderna aims to generate new revenue as demand for its COVID-19 vaccine declines, with analysts forecasting significant sales growth for the RSV vaccine in the coming years. The CDC will vote on usage recommendations next month.

Topics:business#efficacy#fda#health#moderna#mrna#rsv-vaccine
Share this article
  1. US FDA approves Moderna's RSV vaccine with lower-than-expected efficacy in its label  Reuters
  2. Moderna's RSV shot wins FDA approval for use in older adults  The Seattle Times
  3. FDA approves Moderna’s mRNA RSV vaccine for older adults  CNN
  4. Moderna Scores FDA Approval For Its Second Product - Respiratory Syncytial Virus Vaccine  Yahoo Finance
  5. FDA approves Moderna's RSV vaccine for seniors, the company's second-ever product  CNBC

Reading Insights

Total Reads

0

Unique Readers

1

Time Saved

2 min

vs 3 min read

Condensed

86%

541 → 74 words

Want the full story? Read the original article

Read on Reuters